BioWorld

July 28, 2009

View Archived Issues

Avila Raises $30M, Pulls Down $200M Deal with Novartis Fund

Biotech start-up Avila Therapeutics Inc. not only raised $30 million in a Series B financing, but snagged a deal potentially worth $200 million in up-front and milestones plus royalties with Novartis Option Fund. (BioWorld Today) Read More

Cerulean Steps Up 'Tempo,' Gets $10M for Nanoparticles

Read More

GSK Deal, Strong Quarter Get Amgen High Wall Street Marks

Read More

Liraglutide's Good-Data Ride: A Higher Bar for Byetta LAR?

Read More

More Action in the Tools Space: Agilent Buying Varian for $1.5B

Read More

Other News To Note

Read More

Clinic Roundup

Read More